Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40.RBDv
- Development stage
- Phase 2
- Lead developer
- Linkinvax
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CD40.RBDv is a recombinant subunit protein vaccine candidate designed as a bivalent COVID-19 vaccine. It targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and is engineered to enhance immune responses by targeting the antigen to the CD40 receptor on antigen-presenting cells. The vaccine can be administered with or without an adjuvant and is being evaluated as a booster in healthy volunteers. Its mechanism leverages both direct presentation of viral antigens and immunostimulatory effects via engagement of the CD40 pathway, which plays a key role in activating B cells, dendritic cells, and other components of adaptive immunity[1][2][7].
- Other names
- COVID-19 CD40.RBDvCOVID19 CD40.RBDvCOVID 19 CD40.RBDvLinKinVax CD40.RBDv
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on CD40.RBDv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40.RBDv.